Keybank National Association OH Buys 16,825 Shares of IDEXX Laboratories, Inc. $IDXX

Keybank National Association OH grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 422.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,810 shares of the company’s stock after buying an additional 16,825 shares during the quarter. Keybank National Association OH’s holdings in IDEXX Laboratories were worth $13,295,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the second quarter worth approximately $30,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $31,000. Armstrong Advisory Group Inc. raised its holdings in shares of IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in IDEXX Laboratories in the third quarter valued at approximately $35,000. Finally, Ameritas Advisory Services LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $36,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $670.46 on Friday. The firm has a fifty day simple moving average of $705.35 and a two-hundred day simple moving average of $660.81. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $53.54 billion, a PE ratio of 53.17, a P/E/G ratio of 3.61 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company earned $2.80 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. BTIG Research boosted their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Barclays began coverage on IDEXX Laboratories in a report on Monday, December 8th. They set an “overweight” rating and a $850.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.